Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 73
Filter
1.
Eur Cell Mater ; 41: 170-183, 2021 02 13.
Article in English | MEDLINE | ID: mdl-33580967

ABSTRACT

The aim of the present study was to investigate in vivo whether bone morphogenetic protein-7 (BMP-7) was able to promote and accelerate dental implant healing at a low dose in an osteopenic environment by using a delayed drug-release system. Skeletally mature Chinese goats, having physiologically osteopenic (osteoporotic-like) facial bones, served as an animal model. Dental implants were provided with a delayed-release drug-delivery system and BMP-7 was applied at three different dosages. The implants, inserted into healed extraction sockets, were removed 1, 2 and 3 weeks after surgery. Quantification of osseointegration and formation of new bone in the peri- implant space were measured histomorphometrically. Data revealed no evidence of any adverse drug effect at or near the implantation sites. After the first postoperative week, bone neoformation was minimal; after the second week, peri-implant bone formation appeared, particularly in the groups with low dosages of BMP-7. After 3 weeks, new-bone volume was the largest in the group with the lowest (near-physiological) dosage of BMP-7, also showing the highest efficacy of BMP-7. Other dosage or release modes were found to be significantly less effective. BMP-7 was highly efficacious in promoting and accelerating bone formation in the peri-implant space in a hostile osteopenic environment if released by a slow-mode mechanism over time at near physiological activities. Therefore, biological functionalisation of dental implants by a high-power osteogenic factor may improve their healing success in hostile bony environments (osteopenia, osteoporosis, bone atrophy etc.).


Subject(s)
Bone Morphogenetic Protein 7 , Dental Implants , Animals , Bone Morphogenetic Protein 2 , Osseointegration , Osteogenesis
2.
Osteoporos Int ; 31(10): 1913-1923, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32451557

ABSTRACT

Reference values for radius and tibia strength using multiple-stack high-resolution peripheral quantitative computed tomography (HR-pQCT) with homogenized finite element analysis are presented in order to derive critical values improving risk prediction models of osteoporosis. Gender and femoral neck areal bone mineral density (aBMD) were independent predictors of bone strength. INTRODUCTION: The purpose was to obtain reference values for radius and tibia bone strength computed by using the homogenized finite element analysis (hFE) using multiple stacks with a HR-pQCT. METHODS: Male and female healthy participants aged 20-39 years were recruited at the University Hospital of Bern. They underwent interview and clinical examination including hand grip, gait speed and DXA of the hip. The nondominant forearm and tibia were scanned with a double and a triple-stack protocol, respectively, using HR-pQCT (XCT II, SCANCO Medical AG). Bone strength was estimated by using the hFE analysis, and reference values were calculated using quantile regression. Multivariable analyses were performed to identify clinical predictors of bone strength. RESULTS: Overall, 46 women and 41 men were recruited with mean ages of 25.1 (sd 5.0) and 26.2 (sd 5.2) years. Sex-specific reference values for bone strength were established. Men had significantly higher strength for radius (mean (sd) 6640 (1800) N vs. 4110 (1200) N; p < 0.001) and tibia (18,200 (4220) N vs. 11,970 (3150) N; p < 0.001) than women. In the two multivariable regression models with and without total hip aBMD, the addition of neck hip aBMD significantly improved the model (p < 0.001). No clinical predictors of bone strength other than gender and aBMD were identified. CONCLUSION: Reference values for radius and tibia strength using multiple HR-pQCT stacks with hFE analysis are presented and provide the basis to help refining accurate risk prediction models. Femoral neck aBMD and gender were significant predictors of bone strength.


Subject(s)
Radius , Tibia , Absorptiometry, Photon , Adult , Bone Density , Child, Preschool , Female , Hand Strength , Humans , Male , Radius/diagnostic imaging , Reference Values , Tibia/diagnostic imaging , Young Adult
3.
Osteoporos Int ; 30(5): 1125-1135, 2019 May.
Article in English | MEDLINE | ID: mdl-30603840

ABSTRACT

Life expectancy of people living with HIV (PLWH) is reaching similar length as in the general population. Accordingly, age-related comorbidities, including osteoporosis, are increasing. Fracture risk is higher and increases approximately 10 years earlier in PLWH. Classical risk factors of bone fragility are highly prevalent in PLWH but factors specific for HIV infection itself and the type of antiretroviral therapy (ART) (triple combination antiretroviral therapy) regimen (especially tenofovir and protease inhibitors) also contribute to bone loss. The majority of bone loss occurs during virus activity and at initiation of ART (immune reconstitution) and is associated with an increase of bone resorption (upregulation RANKL). Recent data indicate that calcium and vitamin D supplements as ART initiation lower BMD loss. The reduction of tenofovir plasma concentrations with tenofovir alafenamide attenuates BMD loss but it remains unknown whether it will contribute to reduce fracture risk. Hence, special considerations for the management of bone fragility in PLWH are warranted. Based on the current state of epidemiology and pathophysiology of osteoporosis in PLWH, we provide the consensus of the Swiss Association against Osteoporosis on best practice for diagnosis, prevention, and management of osteoporosis in this population. Periodic assessment of fracture risk is indicated in all HIV patients and general preventive measures should be implemented. All postmenopausal women, men above 50 years of age, and patients with other clinical risk for fragility fractures qualify for BMD measurement. An algorithm clarifies when treatment with bisphosphonates and review of ART regimen in favour of more bone-friendly options are indicated.


Subject(s)
HIV Infections/complications , Osteoporosis/etiology , Anti-HIV Agents/adverse effects , Bone Density/drug effects , Bone Density Conservation Agents/therapeutic use , HIV Infections/epidemiology , Humans , Osteoporosis/diagnosis , Osteoporosis/epidemiology , Osteoporosis/therapy , Osteoporotic Fractures/epidemiology , Osteoporotic Fractures/physiopathology , Osteoporotic Fractures/prevention & control , Risk Assessment/methods , Risk Factors , Switzerland/epidemiology
4.
Osteoporos Int ; 28(10): 2967-2973, 2017 10.
Article in English | MEDLINE | ID: mdl-28748386

ABSTRACT

Trabecular bone score (TBS) assesses bone quality in the lumbar spine using dual-energy X-ray absorptiometry (DXA) scans. In postmenopausal women with osteoporosis, denosumab significantly improved TBS independently of bone mineral density (BMD). This practical technique may have a role in managing patients with osteoporosis. INTRODUCTION: TBS, a gray-level texture index determined from lumbar spine DXA scans, correlates with bone microarchitecture and enhances assessment of vertebral fracture risk independently of BMD. In the FREEDOM study, denosumab increased BMD and reduced new vertebral fractures in postmenopausal women with osteoporosis. This retrospective analysis explored the effect of denosumab on TBS and the association between TBS and BMD in FREEDOM. METHODS: Postmenopausal women with lumbar spine or total hip BMD T-score <-2.5 and -4.0 or higher at both sites received placebo or denosumab 60 mg subcutaneously every 6 months. TBS indices were determined from DXA scans at baseline and months 12, 24, and 36 in a subset of 285 women (128 placebo, 157 denosumab) who had TBS values at baseline and ≥1 postbaseline visit. RESULTS: Baseline characteristics were comparable between treatment groups; mean (SD) lumbar spine BMD T-score was -2.79 (0.64), and mean (standard deviation [SD]) TBS was 1.200 (0.101) overall. In the placebo group, BMD and TBS increased by ≤0.2% or decreased from baseline at each visit. In the denosumab group, progressive increases from baseline at 12, 24, and 36 months were observed for BMD (5.7, 7.8, and 9.8%) and TBS (1.4, 1.9, and 2.4%). Percentage changes in TBS were statistically significant compared with baseline (p < 0.001) and placebo (p ≤ 0.014). TBS was largely unrelated to BMD, regardless of treatment, either at baseline or for annual changes from baseline (all r 2 ≤ 0.06). CONCLUSIONS: In postmenopausal women with osteoporosis, denosumab significantly improved TBS independently of BMD.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Cancellous Bone/drug effects , Denosumab/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Absorptiometry, Photon/methods , Aged , Bone Density Conservation Agents/pharmacology , Cancellous Bone/physiopathology , Denosumab/pharmacology , Double-Blind Method , Female , Humans , Lumbar Vertebrae/drug effects , Lumbar Vertebrae/physiopathology , Middle Aged , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/physiopathology , Osteoporotic Fractures/prevention & control , Retrospective Studies , Spinal Fractures/physiopathology , Spinal Fractures/prevention & control
5.
Osteoporos Int ; 28(6): 1995-2002, 2017 06.
Article in English | MEDLINE | ID: mdl-28299378

ABSTRACT

A first intravenous dose of bisphosphonates may be associated with an acute-phase response (APR). In bisphosphonate-naïve women with postmenopausal osteoporosis, the characteristics and frequency of APR may differ by compound. Prior bisphosphonate exposure was predictive of APR risk and severity. INTRODUCTION: Intravenous (IV) administration of bisphosphonates (BP), such as zoledronate (ZOL) and ibandronate (IBN), may be associated with an APR. The characteristics of APR may differ by compound. The aim of the present study was to evaluate the characteristics of APR (rates, signs and symptoms, severity), in the absence of any preventive measure, after a first IV application of ZOL or IBN in patients naïve or previously exposed to BP in a real-world clinical setting. METHODS: This is an open-label prospective exploratory study with two cohorts of consecutive postmenopausal women with osteoporosis treated with either IV ZOL or IBN at the Department of Osteoporosis of the University Hospital of Berne, Switzerland. RESULTS: Intravenous BP was administered to 725 women (411 ZOL and 314 IBN). Prior oral or IV BP use was less frequent in the ZOL group (61.8 vs. 71.7%, p = 0.005). In total, 301 women (41.5%) reported the presence of one or more signs or symptoms of APR with rates for ZOL and IBN of 47.7 and 33.4%, respectively (p < 0.001). Corresponding APR rates in the subgroup of BP-naïve patients were 55.6 and 32.4%, respectively (p < 0.001). The leading APR clinical sign was the presence of post-dose myalgia or arthralgia (68.1%). Prior BP exposure was predictive of both APR risk and severity, and lower serum 25-hydroxy vitamin D (25(OH)D) levels were possibly predictive of severity. CONCLUSIONS: In a real-world setting, APR rates with ZOL and IBN may be higher than reported in randomised controlled trials and may differ by compound, prior BP exposure, and serum 25(OH)D levels.


Subject(s)
Acute-Phase Reaction/chemically induced , Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , Imidazoles/adverse effects , Osteoporosis, Postmenopausal/drug therapy , Aged , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/therapeutic use , Diphosphonates/administration & dosage , Diphosphonates/therapeutic use , Female , Humans , Ibandronic Acid , Imidazoles/administration & dosage , Imidazoles/therapeutic use , Infusions, Intravenous , Middle Aged , Prospective Studies , Risk Factors , Severity of Illness Index , Zoledronic Acid
6.
Eur Cell Mater ; 32: 241-256, 2016 11 18.
Article in English | MEDLINE | ID: mdl-27858400

ABSTRACT

In clinical orthopaedics, total joint replacements and spinal fusions are routine undertakings. Many of the implicated patients suffer from osteoporosis, severe arthrosis or osteopaenia. In individuals thus afflicted, the bony bed lacks the mechanical stability that is a requisite for a firm anchorage of the implant and its functional competence. To promote the bony bondage of an implant it is necessary to induce neo-ossification by the introduction of an osteogenic agent, such as bone morphogenetic protein 2 (BMP-2). Since this growth factor is generally applied in a free form and at high dosages to maximise its osteogenicity, untoward side effects frequently ensue. We hypothesise that the administration of BMP-2 using a suitable delivery vehicle, and its gradual, low dose release therefrom in a cell-mediated manner, would avert the triggering of undesired side effects and enhance its efficacy. To test this postulate, implants of porous titanium were coated with a layer of calcium phosphate into which BMP-2 was biomimetically incorporated at dosages ranging from 0.8 to 500 µg/g of coating material (delivery system) prior to their surgical placement in the tibiae of adult sheep. The volume and the surface area of newly-formed bone were evaluated histomorphometrically after 3 and 6 weeks. The highest values were achieved using BMP-2 dosages of 20 to 100 µg/g of coating: The deposition of bone was confined to the immediate vicinity of the implant and was observed deep within the interstices of its meshwork, to the walls of which it bonded well. The findings of the study attest to the validity of our hypothesis.


Subject(s)
Bone Morphogenetic Protein 2/pharmacology , Implants, Experimental , Osseointegration/drug effects , Titanium/pharmacology , Animals , Cancellous Bone/drug effects , Coated Materials, Biocompatible/pharmacology , Imaging, Three-Dimensional , Kinetics , Models, Animal , Organ Size/drug effects , Porosity , Sheep , Time Factors
7.
Osteoporos Int ; 27(5): 1917-21, 2016 May.
Article in English | MEDLINE | ID: mdl-26694598

ABSTRACT

UNLABELLED: Rebound-associated vertebral fractures may follow treatment discontinuation of highly potent reversible bone antiresorptives, resulting from the synergy of rapid bone resorption and accelerated microdamage accumulation in trabecular bone. INTRODUCTION: The purposes of this study are to characterize rebound-associated vertebral fractures following the discontinuation of a highly potent reversible antiresorptive therapy based on clinical observation and propose a pathophysiological rationale. METHODS: This study is a case report of multiple vertebral fractures early after discontinuation of denosumab therapy in a patient with hormone receptor-positive non-metastatic breast cancer treated with an aromatase inhibitor. RESULTS: Discontinuation of highly potent reversible bone antiresorptives such as denosumab may expose patients to an increased fracture risk due to the joined effects of absent microdamage repair during therapy followed by synchronous excess activation of multiple bone remodelling units at the time of loss-of-effect. We suggest the term rebound-associated vertebral fractures (RVF) for this phenomenon characterized by the presence of multiple new clinical vertebral fractures, associated with either no or low trauma, in a context consistent with the presence of high bone turnover and rapid loss of lumbar spine bone mineral density (BMD) occurring within 3 to 12 months after discontinuation (loss-of-effect) of a reversible antiresorptive therapy in the absence of secondary causes of bone loss or fractures. Unlike atypical femoral fractures that emerge from failure of microdamage repair in cortical bone with long-term antiresorptive treatment, RVF originate from the synergy of rapid bone resorption and accelerated microdamage accumulation in trabecular bone triggered by the discontinuation of highly potent reversible antiresorptives. CONCLUSIONS: Studies are urgently needed to i) prove the underlying pathophysiological processes suggested above, ii) establish the predictive criteria exposing patients to an increased risk of RVF, and iii) determine appropriate treatment regimens to be applied in such patients.


Subject(s)
Bone Density Conservation Agents/administration & dosage , Denosumab/administration & dosage , Osteoporotic Fractures/etiology , Spinal Fractures/etiology , Aromatase Inhibitors/adverse effects , Aromatase Inhibitors/therapeutic use , Bone Density Conservation Agents/therapeutic use , Bone Diseases, Metabolic/chemically induced , Bone Diseases, Metabolic/prevention & control , Breast Neoplasms/drug therapy , Denosumab/therapeutic use , Drug Administration Schedule , Female , Humans , Middle Aged , Withholding Treatment
8.
Osteoporos Int ; 26(12): 2773-83, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26202488

ABSTRACT

UNLABELLED: The FREEDOM study and its Extension provide long-term information about the effects of denosumab for the treatment of postmenopausal osteoporosis. Treatment for up to 8 years was associated with persistent reduction of bone turnover, continued increases in bone mineral density, low fracture incidence, and a favorable benefit/risk profile. INTRODUCTION: This study aims to report the results through year 5 of the FREEDOM Extension study, representing up to 8 years of continued denosumab treatment in postmenopausal women with osteoporosis. METHODS: Women who completed the 3-year FREEDOM study were eligible to enter the 7-year open-label FREEDOM Extension in which all participants are scheduled to receive denosumab, since placebo assignment was discontinued for ethical reasons. A total of 4550 women enrolled in the Extension (2343 long-term; 2207 cross-over). In this analysis, women in the long-term and cross-over groups received denosumab for up to 8 and 5 years, respectively. RESULTS: Throughout the Extension, sustained reduction of bone turnover markers (BTMs) was observed in both groups. In the long-term group, mean bone mineral density (BMD) continued to increase significantly at each time point measured, for cumulative 8-year gains of 18.4 and 8.3 % at the lumbar spine and total hip, respectively. In the cross-over group, mean BMD increased significantly from the Extension baseline for 5-year cumulative gains of 13.1 and 6.2 % at the lumbar spine and total hip, respectively. The yearly incidence of new vertebral and nonvertebral fractures remained low in both groups. The incidence of adverse and serious adverse events did not increase over time. Through Extension year 5, eight events of osteonecrosis of the jaw and two events of atypical femoral fracture were confirmed. CONCLUSIONS: Denosumab treatment for up to 8 years was associated with persistent reductions of BTMs, continued BMD gains, low fracture incidence, and a consistent safety profile.


Subject(s)
Bone Density Conservation Agents/administration & dosage , Denosumab/administration & dosage , Osteoporosis, Postmenopausal/drug therapy , Aged , Aged, 80 and over , Bone Density/drug effects , Bone Density Conservation Agents/adverse effects , Bone Density Conservation Agents/therapeutic use , Bone Remodeling/drug effects , Cross-Over Studies , Denosumab/adverse effects , Denosumab/therapeutic use , Drug Administration Schedule , Female , Humans , Middle Aged , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/physiopathology , Osteoporotic Fractures/prevention & control , Spinal Fractures/physiopathology , Spinal Fractures/prevention & control
9.
Osteoporos Int ; 26(12): 2763-71, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26068295

ABSTRACT

UNLABELLED: Limited data exist on the efficacy of long-term therapies for osteoporosis. In osteoporotic postmenopausal women receiving denosumab for 7 years, nonvertebral fracture rates significantly decreased in years 4-7 versus years 1-3. This is the first demonstration of a further benefit on fracture outcomes with long-term therapy for osteoporosis. INTRODUCTION: This study aimed to evaluate whether denosumab treatment continued beyond 3 years is associated with a further reduction in nonvertebral fracture rates. METHODS: Participants who completed the 3-year placebo-controlled Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM) study were invited to participate in an open-label extension. The present analysis includes 4,074 postmenopausal women with osteoporosis (n = 2,343 long-term; n = 1,731 cross-over) who enrolled in the extension, missed ≤1 dose during their first 3 years of denosumab treatment, and continued into the fourth year of treatment. Comparison of nonvertebral fracture rates during years 1-3 of denosumab with that of the fourth year and with the rate during years 4-7 was evaluated. RESULTS: For the combined group, the nonvertebral fracture rate per 100 participant-years was 2.15 for the first 3 years of denosumab treatment (referent) and 1.36 in the fourth year (rate ratio [RR] = 0.64; 95 % confidence interval (CI) = 0.48 to 0.85, p = 0.003). Comparable findings were observed in the groups separately and when nonvertebral fracture rates during years 1-3 were compared to years 4-7 in the long-term group (RR = 0.79; 95 % CI = 0.62 to 1.00, p = 0.046). Fracture rate reductions in year 4 were most prominent in subjects with persisting low hip bone mineral density (BMD). CONCLUSIONS: Denosumab treatment beyond 3 years was associated with a further reduction in nonvertebral fracture rate that persisted through 7 years of continuous denosumab administration. The degree to which denosumab further reduces nonvertebral fracture risk appears influenced by the hip bone density achieved with initial therapy.


Subject(s)
Bone Density Conservation Agents/administration & dosage , Bone Density/drug effects , Denosumab/administration & dosage , Osteoporosis, Postmenopausal/drug therapy , Osteoporotic Fractures/prevention & control , Aged , Aged, 80 and over , Bone Density Conservation Agents/therapeutic use , Denosumab/therapeutic use , Double-Blind Method , Drug Administration Schedule , Female , Follow-Up Studies , Hip Joint/physiopathology , Humans , Incidence , Middle Aged , Osteoporosis, Postmenopausal/epidemiology , Osteoporosis, Postmenopausal/physiopathology , Osteoporotic Fractures/epidemiology , Osteoporotic Fractures/physiopathology
10.
Spinal Cord ; 53(9): 701-4, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25987003

ABSTRACT

STUDY DESIGN: Retrospective data analysis. OBJECTIVES: To document fracture characteristics, management and related complications in individuals with traumatic spinal cord injury (SCI). SETTING: Rehabilitation centre for SCI individuals. METHOD: Patients' records were reviewed. Patients with traumatic SCI and extremity fractures that had occurred after SCI were included. Patient characteristics, fractured bone, fracture localisation, severity and management (operative/conservative), and fracture-related complications were extracted. RESULTS: A total of 156 long-bone fractures in 107 SCI patients (34 women and 73 men) were identified. The majority of patients were paraplegics (77.6%) and classified as American Spinal Injury Association Impairment Scale A (86.0%). Only the lower extremities were affected, whereby the femur (60.9% of all fractures) was fractured more frequently than the lower leg (39.1%). A total of 70 patients (65.4%) had one fracture, whereas 37 patients (34.6%) had two or more fractures. Simple or extraarticular fractures were most common (75.0%). Overall, 130 (83.3%) fractures were managed operatively. Approximately half of the femur fractures (48.2%) were treated with locking compression plates. In the lower leg, fractures were mainly managed with external fixation (48.8%). Conservative fracture management was applied in 16.7% of the cases and consisted of braces or a well-padded soft cast. Fracture-associated complications were present in 13.5% of the cases but did not differ significantly between operative (13.1%) and conservative (15.4%) fracture management. CONCLUSION: SCI was associated with simple or extraarticular fractures of the distal femur and the lower leg. Fractures were mainly managed operatively with a low complication rate.


Subject(s)
Fractures, Bone/complications , Fractures, Bone/epidemiology , Leg Injuries/complications , Leg Injuries/epidemiology , Spinal Cord Injuries/complications , Spinal Cord Injuries/epidemiology , Adult , Female , Fractures, Bone/therapy , Humans , Leg Injuries/therapy , Male , Paraplegia/complications , Paraplegia/epidemiology , Paraplegia/physiopathology , Postoperative Complications/epidemiology , Rehabilitation Centers , Retrospective Studies , Severity of Illness Index , Spinal Cord Injuries/physiopathology
11.
Osteoarthritis Cartilage ; 23(3): 334-50, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25534362

ABSTRACT

OBJECTIVE: The repair of cartilaginous lesions within synovial joints is still an unresolved and weighty clinical problem. Although research activity in this area has been indefatigably sustained, no significant progress has been made during the past decade. The aim of this educational review is to heighten the awareness amongst students and scientists of the basic issues that must be tackled and resolved before we can hope to escape from the whirlpool of stagnation into which we have fallen: cartilage repair redivivus! DESIGN: Articular-cartilage lesions may be induced traumatically (e.g., by sports injuries and occupational accidents) or pathologically during the course of a degenerative disease (e.g., osteoarthritis). This review addresses the biological basis of cartilage repair and surveys current trends in treatment strategies, focussing on those that are most widely adopted by orthopaedic surgeons [viz., abrasive chondroplasty, microfracturing/microdrilling, osteochondral grafting and autologous-chondrocyte implantation (ACI)]. Also described are current research activities in the field of cartilage-tissue engineering, which, as a therapeutic principle, holds more promise for success than any other experimental approach. RESULTS AND CONCLUSIONS: Tissue engineering aims to reconstitute a tissue both structurally and functionally. This process can be conducted entirely in vitro, initially in vitro and then in vivo (in situ), or entirely in vivo. Three key constituents usually form the building blocks of such an approach: a matrix scaffold, cells, and signalling molecules. Of the proposed approaches, none have yet advanced beyond the phase of experimental development to the level of clinical induction. The hurdles that need to be surmounted for ultimate success are discussed.


Subject(s)
Arthroplasty, Subchondral , Bone Transplantation , Cartilage, Articular/surgery , Cartilage/transplantation , Chondrocytes/transplantation , Osteoarthritis/surgery , Cartilage, Articular/injuries , Humans , Orthopedic Procedures , Osteoarthritis/therapy , Tissue Engineering
12.
Osteoporos Int ; 25(7): 1945-51, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24760244

ABSTRACT

UNLABELLED: Treatment effects over 2 years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug. INTRODUCTION: The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from anteroposterior spine dual X-ray absorptiometry (DXA) scans. The potential role of TBS for monitoring treatment response with bone-active substances is not established. The aim of this study was to compare the effects of recombinant human 1-34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis. METHODS: Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (N = 65) or quarterly intravenous IBN (N = 122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared. RESULTS: Baseline characteristics (overall mean ± SD) were similar between groups in terms of age 67.9 ± 7.4 years, body mass index 23.8 ± 3.8 kg/m(2), BMD L1-L4 0.741 ± 0.100 g/cm(2), and TBS 1.208 ± 0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 % ± 6.3 vs. +2.9 % ± 3.3 and +4.3 % ± 6.6 vs. +0.3 % ± 4.1, respectively; P < 0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (r (2) = 0.04) with no correlation between the changes in BMD and TBS over 24 months. CONCLUSIONS: In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Diphosphonates/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Teriparatide/therapeutic use , Absorptiometry, Photon/methods , Aged , Bone Density Conservation Agents/pharmacology , Diphosphonates/pharmacology , Drug Evaluation/methods , Female , Humans , Ibandronic Acid , Injections, Intravenous , Injections, Subcutaneous , Lumbar Vertebrae/physiopathology , Middle Aged , Osteoporosis, Postmenopausal/physiopathology , Retrospective Studies , Teriparatide/pharmacology , Treatment Outcome
13.
Maturitas ; 77(3): 287-93, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24485216

ABSTRACT

BACKGROUND: In postmenopausal women, yearly intravenous zoledronate (ZOL) compared to placebo (PLB) significantly increased bone mineral density (BMD) at lumbar spine (LS), femoral neck (FN), and total hip (TH) and decreased fracture risk. The effects of ZOL on BMD at the tibial epiphysis (T-EPI) and diaphysis (T-DIA) are unknown. METHODS: A randomized controlled ancillary study of the HORIZON trial was conducted at the Department of Osteoporosis of the University Hospital of Berne, Switzerland. Women with ≥1 follow-up DXA measurement who had received ≥1 dose of either ZOL (n=55) or PLB (n=55) were included. BMD was measured at LS, FN, TH, T-EPI, and T-DIA at baseline, 6, 12, 24, and 36 months. Morphometric vertebral fractures were assessed. Incident clinical fractures were recorded as adverse events. RESULTS: Baseline characteristics were comparable with those in HORIZON and between groups. After 36 months, BMD was significantly higher in women treated with ZOL vs. PLB at LS, FN, TH, and T-EPI (+7.6%, +3.7%, +5.6%, and +5.5%, respectively, p<0.01 for all) but not T-DIA (+1.1%). The number of patients with ≥1 incident non-vertebral or morphometric fracture did not differ between groups (9 ZOL/11 PLB). Mean changes in BMD did not differ between groups with and without incident fracture, except that women with an incident non-vertebral fracture had significantly higher bone loss at predominantly cortical T-DIA (p=0.005). CONCLUSION: ZOL was significantly superior to PLB at T-EPI but not at T-DIA. Women with an incident non-vertebral fracture experienced bone loss at T-DIA.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Diphosphonates/therapeutic use , Fractures, Bone , Imidazoles/therapeutic use , Osteoporosis, Postmenopausal , Tibia/metabolism , Aged , Aged, 80 and over , Bone Density Conservation Agents/pharmacology , Diphosphonates/pharmacology , Female , Fractures, Bone/etiology , Fractures, Bone/prevention & control , Humans , Imidazoles/pharmacology , Incidence , Osteoporosis, Postmenopausal/complications , Osteoporosis, Postmenopausal/drug therapy , Osteoporosis, Postmenopausal/metabolism , Zoledronic Acid
15.
Osteoporos Int ; 23(11): 2579-89, 2012 Nov.
Article in English | MEDLINE | ID: mdl-22222755

ABSTRACT

UNLABELLED: FRAX-based cost-effective intervention thresholds in the Swiss setting were determined. Assuming a willingness to pay at 2× Gross Domestic Product per capita, an intervention aimed at reducing fracture risk in women and men with a 10-year probability for a major osteoporotic fracture at or above 15% is cost-effective. INTRODUCTION: The fracture risk assessment algorithm FRAX® has been recently calibrated for Switzerland. The aim of the present analysis was to determine FRAX-based fracture probabilities at which intervention becomes cost-effective. METHODS: A previously developed and validated state transition Markov cohort model was populated with Swiss epidemiological and cost input parameters. Cost-effective FRAX-based intervention thresholds (cost-effectiveness approach) and the cost-effectiveness of intervention with alendronate (original molecule) in subjects with a FRAX-based fracture risk equivalent to that of a woman with a prior fragility fracture and no other risk factor (translational approach) were calculated based on the Swiss FRAX model and assuming a willingness to pay of 2 times Gross Domestic Product per capita for one Quality-adjusted Life-Year. RESULTS: In Swiss women and men aged 50 years and older, drug intervention aimed at decreasing fracture risk was cost-effective with a 10-year probability for a major osteoporotic fracture at or above 13.8% (range 10.8% to 15.0%) and 15.1% (range 9.9% to 19.9%), respectively. Age-dependent variations around these mean values were modest. Using the translational approach, treatment was cost-effective or cost-saving after the age 60 years in women and 55 in men who had previously sustained a fragility fracture. Using the latter approach leads to considerable underuse of the current potential for cost-effective interventions against fractures. CONCLUSIONS: Using a FRAX-based intervention threshold of 15% for both women and men should permit cost-effective access to therapy to patients at high fracture probability based on clinical risk factors and thereby contribute to further reduce the growing burden of osteoporotic fractures in Switzerland.


Subject(s)
Osteoporotic Fractures/prevention & control , Age Distribution , Aged , Aged, 80 and over , Alendronate/economics , Alendronate/therapeutic use , Algorithms , Bone Density Conservation Agents/economics , Bone Density Conservation Agents/therapeutic use , Cost-Benefit Analysis , Drug Costs/statistics & numerical data , Female , Humans , Male , Middle Aged , Osteoporotic Fractures/economics , Osteoporotic Fractures/epidemiology , Quality-Adjusted Life Years , Risk Assessment/methods , Sensitivity and Specificity , Switzerland/epidemiology
16.
Osteoporos Int ; 23(3): 829-39, 2012 Mar.
Article in English | MEDLINE | ID: mdl-21625882

ABSTRACT

UNLABELLED: In Switzerland, the number, incidence, and cost of acute hospitalizations for major osteoporotic fractures (MOF) and major cardiovascular events (MCE) increased in both women and men between 2000 and 2008, although the mean length of stay (LOS) was significantly reduced. Similar trend patterns were observed for hip fractures and strokes (decrease) and nonhip fractures and acute myocardial infarctions (increase). INTRODUCTION: The purpose of this study was to compare the trends and epidemiological characteristics of hospitalizations for MOF and other frequent diseases between years 2000 and 2008 in Switzerland. METHODS: Trends in the number, age-standardized incidence, mean LOS, and cost of hospitalized MOF and MCE (acute myocardial infarction, stroke, and heart failure) were compared in women and men aged ≥ 45 years, based on data from the Swiss Federal Statistical Office. RESULTS: Between 2000 and 2008, the incidence of acute hospitalizations for MOF increased by 3.4% in women and 0.3% in men. In both sexes, a significant decrease in hip fractures (-15.0% and -11.0%) was compensated by a concomitant, significant increase in nonhip fractures (+24.8% and +13.8%). Similarly, the incidence of acute hospitalizations for MCE increased by 4.4% in women and 8.2% in men, as an aggregated result from significantly increasing acute myocardial infarctions and significantly decreasing strokes. While the mean LOS in the acute inpatient setting decreased almost linearly between years 2000 and 2008 in all indications, the inpatient costs increased significantly (p < 0.001) for MOF (+30.1% and +42.7%) and MCE (+22.6% and +47.1%) in women and men, respectively. CONCLUSIONS: Between years 2000 and 2008, the burden of hospitalized osteoporotic fractures to the Swiss healthcare system has continued to increase in both sexes. In women, this burden was significantly higher than that of MCE and the gap widened over time.


Subject(s)
Hospitalization/trends , Osteoporotic Fractures/epidemiology , Age Distribution , Aged , Aged, 80 and over , Cardiovascular Diseases/economics , Cardiovascular Diseases/epidemiology , Female , Hip Fractures/economics , Hip Fractures/epidemiology , Hospital Costs/statistics & numerical data , Hospital Costs/trends , Hospitalization/economics , Hospitalization/statistics & numerical data , Humans , Incidence , Length of Stay/statistics & numerical data , Length of Stay/trends , Male , Middle Aged , Osteoporotic Fractures/economics , Sex Factors , Switzerland/epidemiology
17.
Swiss Med Wkly ; 141: w13297, 2011.
Article in English | MEDLINE | ID: mdl-22057669

ABSTRACT

To prevent osteoporotic fracture occurrence, a variety of treatment regimens with different mechanisms of action is available. The antiresorptive bisphosphonate drugs are currently the most commonly prescribed agents in the management of patients with osteoporosis. The recombinant amino-terminal fragment of human parathyroid hormone (Teriparatide) is a bone anabolic agent which reduces fracture risk by increasing bone mass and improving bone microarchitecture. Teriparatide treatment reduces vertebral and non-vertebral fracture risk markedly in women and men with idiopathic osteoporosis, or with glucocorticoid-induced osteoporosis. Teriparatide should thus be considered as first line treatment for postmenopausal women and for men with severe osteoporosis.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Osteoporosis/drug therapy , Teriparatide/therapeutic use , Aged , Bone Density , Female , Fractures, Bone/prevention & control , Humans , Male , Middle Aged , Osteoporosis/physiopathology
19.
J Clin Endocrinol Metab ; 96(6): 1727-36, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21411557

ABSTRACT

CONTEXT: The FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months) trial showed denosumab significantly reduced the risk of fractures in postmenopausal women with osteoporosis. OBJECTIVE: We evaluated the effect of denosumab on the incidence of new vertebral and hip fractures in subgroups of women at higher risk for these fractures. DESIGN: FREEDOM was a 3-yr, randomized, double-blind, placebo-controlled, phase 3 trial. PARTICIPANTS AND SETTING: Postmenopausal women (N = 7808) with osteoporosis were enrolled at 213 study sites worldwide. INTERVENTIONS: Subjects received s.c. denosumab (60 mg) or placebo every 6 months and daily supplements of calcium (≥1000 mg) and vitamin D (≥400 IU). MAIN OUTCOME MEASURES: This post hoc analysis evaluated fracture incidence in women with known risk factors for fractures including multiple and/or moderate or severe prevalent vertebral fractures, aged 75 yr or older, and/or femoral neck bone mineral density T-score of -2.5 or less. RESULTS: Compared with placebo, denosumab significantly reduced the risk of new vertebral fractures in women with multiple and/or severe prevalent vertebral fractures (16.6% placebo vs. 7.5% denosumab; P < 0.001). Similarly, denosumab significantly reduced the risk of hip fractures in subjects aged 75 yr or older (2.3% placebo vs. 0.9% denosumab; P < 0.01) or with a baseline femoral neck bone mineral density T-score of -2.5 or less (2.8% placebo vs. 1.4% denosumab; P = 0.02). These risk reductions in higher-risk individuals were consistent with those seen in patients at lower risk of fracture. CONCLUSIONS: Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at higher risk for fracture. These results highlight the consistent antifracture efficacy of denosumab in patients with varying degrees of fracture risk.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Hip Fractures/epidemiology , Hip Fractures/prevention & control , RANK Ligand/therapeutic use , Spinal Fractures/epidemiology , Spinal Fractures/prevention & control , Aged , Aged, 80 and over , Antibodies, Monoclonal, Humanized , Denosumab , Double-Blind Method , Female , Hip Fractures/etiology , Humans , Incidence , Osteoporosis, Postmenopausal/complications , Postmenopause , Risk , Spinal Fractures/etiology , Treatment Outcome
20.
Osteoporos Int ; 22(9): 2487-97, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21153020

ABSTRACT

UNLABELLED: In Switzerland, the total number and incidence of hospitalizations for major osteoporotic fractures increased between years 2000 and 2007, while hospitalizations due to hip fracture decreased. The cost impact of shorter hospital stays was offset by the increasing cost per day of hospitalization. INTRODUCTION: The aim of the study was to establish the trends and epidemiological characteristics of hospitalizations for major osteoporotic fractures (MOF) between years 2000 and 2007 in Switzerland. METHODS: Sex- and age-specific trends in the number and crude and age-standardized incidences of hospitalized MOF (hip, clinical spine, distal radius, and proximal humerus) in women and men aged ≥45 years were analyzed, together with the number of hospital days and cost of hospitalization, based on data from the Swiss Federal Statistical Office hospital database and population statistics. RESULTS: Between 2000 and 2007, the absolute number of hospitalizations for MOF increased by 15.9% in women and 20.0% in men, mainly due to an increased number of non-hip fractures (+37.7% in women and +39.7% in men). Hospitalizations for hip fractures were comparatively stable (-1.8% in women and +3.3% in men). In a rapidly aging population, in which the number of individuals aged ≥45 years grew by 11.1% (women) and 14.6% (men) over the study period, the crude and age-standardized incidences of hospitalizations decreased for hip fractures and increased for non-hip MOF, both in women and men. The length of hospital stay decreased for all MOF in women and men, the cost impact of which was offset by an increase in the daily costs of hospitalization. CONCLUSIONS: Between years 2000 and 2007, hospitalizations for MOF continued to increase in Switzerland, driven by an increasing number and incidence of hospitalizations for non-hip fractures, although the incidence of hip fractures has declined.


Subject(s)
Hip Fractures/epidemiology , Hospitalization/trends , Length of Stay/trends , Osteoporotic Fractures/epidemiology , Age Distribution , Aged , Aged, 80 and over , Female , Hip Fractures/economics , Hospital Costs/statistics & numerical data , Hospitalization/economics , Humans , Length of Stay/economics , Male , Middle Aged , Osteoporotic Fractures/economics , Sex Distribution , Switzerland/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...